CSL Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

CSL yıllık ortalama 3.2% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 13.2% annual. Gelirler growing yılda ortalama 11.2% oranında artmaktadır. CSL'in özkaynak karlılığı 14% ve net marjı 17.9%'dir.

Anahtar bilgiler

3.2%

Kazanç büyüme oranı

1.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi	9.6%
Gelir büyüme oranı	11.2%
Özkaynak getirisi	14.0%
Net Marj	17.9%
Sonraki Kazanç Güncellemesi	10 Feb 2025

Yakın geçmiş performans güncellemeleri

Recent updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Gelir ve Gider Dağılımı

CSL nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

ASX:CSL Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	14,800	2,642	2,381	1,428
31 Mar 24	14,490	2,557	2,305	1,386
31 Dec 23	14,179	2,472	2,277	1,312
30 Sep 23	13,745	2,333	2,317	1,274
30 Jun 23	13,310	2,194	2,308	1,266
31 Mar 23	12,507	2,156	2,168	1,265
31 Dec 22	11,705	2,118	2,028	1,263
30 Sep 22	11,133	2,186	1,839	1,210
30 Jun 22	10,562	2,255	1,649	1,156
31 Mar 22	10,587	2,290	1,711	1,108
31 Dec 21	10,612	2,325	1,773	1,060
30 Sep 21	10,461	2,350	1,742	1,031
30 Jun 21	10,310	2,375	1,712	1,001
31 Mar 21	10,145	2,520	1,612	953
31 Dec 20	9,980	2,665	1,511	904
30 Sep 20	9,565	2,384	1,550	913
30 Jun 20	9,151	2,103	1,588	922
31 Mar 20	9,048	2,054	1,557	904
31 Dec 19	8,944	2,006	1,527	886
30 Sep 19	8,742	1,962	1,484	859
30 Jun 19	8,539	1,919	1,442	832
31 Mar 19	8,406	1,861	1,441	791
31 Dec 18	8,274	1,803	1,441	751
30 Sep 18	8,094	1,766	1,371	726
30 Jun 18	7,915	1,729	1,301	702
31 Mar 18	7,666	1,674	1,251	713
31 Dec 17	7,417	1,618	1,200	723
30 Sep 17	7,182	1,478	1,191	695
30 Jun 17	6,947	1,337	1,182	667
31 Mar 17	6,802	1,333	1,118	642
31 Dec 16	6,656	1,329	1,055	617
30 Sep 16	6,386	1,286	1,033	615
30 Jun 16	6,115	1,242	1,011	614
31 Mar 16	5,983	1,324	954	564
31 Dec 15	5,850	1,406	897	513
30 Sep 15	5,654	1,392	841	488
30 Jun 15	5,459	1,379	786	463
31 Mar 15	5,482	1,366	768	467
31 Dec 14	5,505	1,354	750	471
30 Sep 14	5,420	1,330	773	468
30 Jun 14	5,335	1,307	797	466
31 Mar 14	5,189	1,270	803	466
31 Dec 13	5,042	1,233	810	466

Kaliteli Kazançlar: CSL yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: CSL 'nin mevcut net kar marjları (17.9%) geçen yılın (16.5%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CSL şirketinin kazancı son 5 yılda yılda 3.2% oranında arttı.

Büyüme Hızlandırma: CSL 'un son bir yıldaki kazanç büyümesi ( 20.4% ) 5 yıllık ortalamasını (yıllık 3.2% ) aşıyor.

Kazançlar vs. Sektör: CSL geçen yılki kazanç büyümesi ( 20.4% ) Biotechs sektörünün 4% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: CSL 'nin Özsermaye Getirisi ( 14% ) düşük olarak değerlendiriliyor.

CSL Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

First half 2024 earnings: EPS misses analyst expectations

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued